75932-02-4

Basic information

• Product Name: N-α,N-ε-di-Fmoc-D-lysine
• Synonyms: N-α,N-ε-di-Fmoc-D-lysine;N-a,N-e-di-Fmoc-D-lysine;N-.ALPHA.,N-.EPSILON.-DI-FMOC-D-LYSINE;(R)-1,13-di(9H-fluoren-9-yl)-3,11-dioxo-2,12-dioxa-4,10-diazatridecane-5-carboxylic acid;D-Lysine, N2,N6-bis[(9H-fluoren-9-ylMethoxy)carbonyl]-;FMoc-D-Lys(FMoc)-OH N-α,N-ε-di-FMoc-D-lysine;N2,N6-Bis-FMoc-D-lysine;N2,N6-Bis[(9H-fluoren-9-ylMethoxy)carbonyl]lysine
• CAS NO: 75932-02-4
• Molecular Formula: C₃₆H₃₄N₂O₆
• Molecular Weight: 590.673
• Mol File: 75932-02-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: ～130°C
• Appearance: /Solid
• Storage Temp.: Store at 0-5°C
• CAS DataBase Reference: N-α,N-ε-di-Fmoc-D-lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N-α,N-ε-di-Fmoc-D-lysine(75932-02-4)
• EPA Substance Registry System: N-α,N-ε-di-Fmoc-D-lysine(75932-02-4)

Safety Data

• Hazardous Substances Data: 75932-02-4(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Upstream product

• 56-87-1 L-lysine 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 28920-44-7 (9H-fluoren-9-yl)methyl azidoformate 
• 7274-88-6 D-lysine hydrochloride 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 657-27-2 L-Lysine hydrochloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 56-87-1 L-lysine 
• 439286-58-5 (S)-2,6-Diamino-hexanoic acid {2-[2-(2,4-dichloro-phenoxy)-acetylamino]-ethyl}-amide 
• 745795-93-1 N-(N^α,N^ε-bis-Fmoc-L-Lys)-O-(4,4'-dimethoxytrityl)-O'-(tert-butyldimethylsilyl)diethanolamine 
• 912557-27-8 {(S)-2-[(S)-2-(2-{(R)-2-[(S)-2,6-Bis-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoylamino]-3-tert-butyldisulfanyl-propionylamino}-acetylamino)-3-methyl-butyrylamino]-3-phenyl-propionylamino}-acetic acid (2E,4E)-hexa-2,4-dienyl ester 

Relevant articles and documents

New conjugates of antitumor antibiotic doxorubicin with water-soluble galactomannan: Synthesis and biological activity

New water-soluble conjugates in the form of Schiff bases (DGM-1 and DGM-2) were prepared by the interaction of water-soluble periodate-oxidized galactomannan with doxorubicin or N-(L-lysyl)doxorubicin, respectively. The water-soluble galactomannan (DAVANAT, a commercial product of Pro-Pharmaceuticals company) was obtained by partial acidic hydrolysis of high-molecular-mass galactomannan from Cyamopsis tetragonoloba (guar gum) seeds. The conjugate stability was studied in aqueous solutions. The DGM-1 anti-proliferative activity was comparable with that of doxorubicin on three models: cell lines of murine melanoma B16-F1 and human breast cancer MCF-7 (HTB-22) and human colon cancer HT-29 (HTB-38). DGM-2 was poorly active in all the three tests. DGM-1 can thus be regarded as a high-molecular-mass depot form of doxorubicin.

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Studies on peptides. CLX. Synthesis of a 33-residue peptide corresponding to the entire amino acid sequence of human cholecystokinin (hCCK-33)

-